Susan J Bartlett1, Vivian P Bykerk2, Roxanne Cooksey2, Ernest H Choy2, Rieke Alten2, Robin Christensen2, Daniel E Furst2, Francis Guillemin2, Serena Halls2, Sarah Hewlett2, Amye L Leong2, Anne Lyddiatt2, Lyn March2, Pamela Montie2, Ana Maria Orbai2, Christoph Pohl2, Marieke Scholte Voshaar2, Thasia G Woodworth2, Clifton O Bingham2. 1. From McGill University, Montreal, Quebec, Canada; Johns Hopkins University, Baltimore, Maryland; Hospital for Special Surgery, New York, New York, USA; Swansea University, Swansea; Cardiff University, Cardiff, UK; Schlosspark-Klinik, University Medicine Berlin, Berlin, Germany; The Parker Institute, Copenhagen University Hospital at Frederiksberg, Copenhagen, Denmark; University of California, Los Angeles, California, USA; University of Lorraine, Nancy, France; University of the West of England, Bristol, UK; Healthy Motivation, Santa Barbara, California, USA; University of Sydney, Sydney, Australia; and University of Twente, Enschede, The Netherlands.S.J. Bartlett, PhD, McGill University; and Johns Hopkins University; V.P. Bykerk, MD, Hospital for Special Surgery; R. Cooksey, MSc, Swansea University; E.H. Choy, MD, Cardiff University; R. Alten, Schlosspark-Klinik, University Medicine Berlin; R. Christensen, PhD, Parker Institute, Copenhagen University Hospital at Frederiksberg; D.E. Furst, MD, University of California, Los Angeles; F. Guillemin, MD, PhD, University of Lorraine; S. Halls, MSc; S. Hewlett, PhD, RN, University of the West of England; A.L. Leong, Healthy Motivation; A. Lyddiatt; University of Sydney; L. March, MD, PhD; P. Montie; A.M. Orbai, MD, MHS, Johns Hopkins University; C. Pohl, MD, Schlosspark-Klinik, University Medicine; M. Scholte Voshaar, University of Twente; T.G. Woodworth, MD, University of California, Los Angeles; and C.O. Bingham 3rd, MD, Johns Hopkins University. Susan.bartlett@mcgill.ca. 2. From McGill University, Montreal, Quebec, Canada; Johns Hopkins University, Baltimore, Maryland; Hospital for Special Surgery, New York, New York, USA; Swansea University, Swansea; Cardiff University, Cardiff, UK; Schlosspark-Klinik, University Medicine Berlin, Berlin, Germany; The Parker Institute, Copenhagen University Hospital at Frederiksberg, Copenhagen, Denmark; University of California, Los Angeles, California, USA; University of Lorraine, Nancy, France; University of the West of England, Bristol, UK; Healthy Motivation, Santa Barbara, California, USA; University of Sydney, Sydney, Australia; and University of Twente, Enschede, The Netherlands.S.J. Bartlett, PhD, McGill University; and Johns Hopkins University; V.P. Bykerk, MD, Hospital for Special Surgery; R. Cooksey, MSc, Swansea University; E.H. Choy, MD, Cardiff University; R. Alten, Schlosspark-Klinik, University Medicine Berlin; R. Christensen, PhD, Parker Institute, Copenhagen University Hospital at Frederiksberg; D.E. Furst, MD, University of California, Los Angeles; F. Guillemin, MD, PhD, University of Lorraine; S. Halls, MSc; S. Hewlett, PhD, RN, University of the West of England; A.L. Leong, Healthy Motivation; A. Lyddiatt; University of Sydney; L. March, MD, PhD; P. Montie; A.M. Orbai, MD, MHS, Johns Hopkins University; C. Pohl, MD, Schlosspark-Klinik, University Medicine; M. Scholte Voshaar, University of Twente; T.G. Woodworth, MD, University of California, Los Angeles; and C.O. Bingham 3rd, MD, Johns Hopkins University.
Abstract
OBJECTIVE: The Outcome Measures in Rheumatology (OMERACT) Rheumatoid Arthritis (RA) Flare Group was established to develop an approach to identify and measure RA flares. An overview of our OMERACT 2014 plenary is provided. METHODS: Feasibility and validity of flare domains endorsed at OMERACT 11 (2012) were described based on initial data from 3 international studies collected using a common set of questions specific to RA flare. Mean flare frequency, severity, and duration data were presented, and domain scores were compared by flare status to examine known-groups validity. Breakout groups provided input for stiffness, self-management, contextual factors, and measurement considerations. RESULTS: Flare data from 501 patients in an observational study indicated 39% were in flare, with mean (SD) severity of 6.0 (2.6) and 55% lasting > 14 days. Pain, physical function, fatigue, participation, and stiffness scores averaged ≥ 2 times higher (2 of 11 points) in flaring individuals. Correlations between flare domains and corresponding legacy instruments were obtained: r = 0.46 to 0.93. A combined definition (patient report of flare and 28-joint Disease Activity Score increase) was evaluated in 2 other trials, with similar results. Breakout groups debated specific measurement issues. CONCLUSION: These data contribute initial evidence of feasibility and content validation of the OMERACT RA Flare Core Domain Set. Our research agenda for OMERACT 2016 includes establishing duration/intensity criteria and developing criteria to identify RA flares using existing disease activity measures. Ongoing work will also address discordance between patient and physician ratings, facilitate application of flare criteria to clinical care, elucidate the role of self-management, and finalize recommendations for RA flare measurement.
OBJECTIVE: The Outcome Measures in Rheumatology (OMERACT) Rheumatoid Arthritis (RA) Flare Group was established to develop an approach to identify and measure RA flares. An overview of our OMERACT 2014 plenary is provided. METHODS: Feasibility and validity of flare domains endorsed at OMERACT 11 (2012) were described based on initial data from 3 international studies collected using a common set of questions specific to RA flare. Mean flare frequency, severity, and duration data were presented, and domain scores were compared by flare status to examine known-groups validity. Breakout groups provided input for stiffness, self-management, contextual factors, and measurement considerations. RESULTS: Flare data from 501 patients in an observational study indicated 39% were in flare, with mean (SD) severity of 6.0 (2.6) and 55% lasting > 14 days. Pain, physical function, fatigue, participation, and stiffness scores averaged ≥ 2 times higher (2 of 11 points) in flaring individuals. Correlations between flare domains and corresponding legacy instruments were obtained: r = 0.46 to 0.93. A combined definition (patient report of flare and 28-joint Disease Activity Score increase) was evaluated in 2 other trials, with similar results. Breakout groups debated specific measurement issues. CONCLUSION: These data contribute initial evidence of feasibility and content validation of the OMERACT RA Flare Core Domain Set. Our research agenda for OMERACT 2016 includes establishing duration/intensity criteria and developing criteria to identify RA flares using existing disease activity measures. Ongoing work will also address discordance between patient and physician ratings, facilitate application of flare criteria to clinical care, elucidate the role of self-management, and finalize recommendations for RA flare measurement.
Authors: Jean-Marie Berthelot; Michel De Bandt; Jacques Morel; Fatima Benatig; Arnaud Constantin; Philippe Gaudin; Xavier Le Loet; Jean-Francis Maillefert; Olivier Meyer; Thao Pham; Alain Saraux; Elisabeth Solau-Gervais; Elisabeth Spitz; Daniel Wendling; Bruno Fautrel; Francis Guillemin Journal: Ann Rheum Dis Date: 2011-11-09 Impact factor: 19.103
Authors: Jasvinder A Singh; Daniel E Furst; Aseem Bharat; Jeffrey R Curtis; Arthur F Kavanaugh; Joel M Kremer; Larry W Moreland; James O'Dell; Kevin L Winthrop; Timothy Beukelman; S Louis Bridges; W Winn Chatham; Harold E Paulus; Maria Suarez-Almazor; Claire Bombardier; Maxime Dougados; Dinesh Khanna; Charles M King; Amye L Leong; Eric L Matteson; John T Schousboe; Eileen Moynihan; Karen S Kolba; Archana Jain; Elizabeth R Volkmann; Harsh Agrawal; Sangmee Bae; Amy S Mudano; Nivedita M Patkar; Kenneth G Saag Journal: Arthritis Care Res (Hoboken) Date: 2012-05 Impact factor: 4.794
Authors: Peter Tugwell; Maarten Boers; Maria-Antonietta D'Agostino; Dorcas Beaton; Annelies Boonen; Clifton O Bingham; Ernest Choy; Philip G Conaghan; Maxime Dougados; Catia Duarte; Daniel E Furst; Francis Guillemin; Laure Gossec; Turid Heiberg; Désirée M van der Heijde; Sarah Hewlett; John R Kirwan; Tore K Kvien; Robert B Landewé; Philip J Mease; Mikkel Østergaard; Lee Simon; Jasvinder A Singh; Vibeke Strand; George Wells Journal: J Rheumatol Date: 2014-04-01 Impact factor: 4.666
Authors: Vivian P Bykerk; Shahin Jamal; Gilles Boire; Carol A Hitchon; Boulos Haraoui; Janet E Pope; J Carter Thorne; Ye Sun; Edward C Keystone Journal: J Rheumatol Date: 2012-08-15 Impact factor: 4.666
Authors: Ana-Maria Orbai; Katherine C Smith; Susan J Bartlett; Elaine De Leon; Clifton O Bingham Journal: Arthritis Care Res (Hoboken) Date: 2014-11 Impact factor: 4.794
Authors: Clifton O Bingham; Christoph Pohl; Thasia G Woodworth; Sarah E Hewlett; James E May; Mahboob U Rahman; James P Witter; Daniel E Furst; C Vibeke Strand; Maarten Boers; Rieke E Alten Journal: J Rheumatol Date: 2009-08-14 Impact factor: 4.666
Authors: Aatke van der Maas; Elisabeth Lie; Robin Christensen; Ernest Choy; Yaël A de Man; Piet van Riel; Thasia Woodworth; Alfons A den Broeder Journal: Ann Rheum Dis Date: 2012-11-23 Impact factor: 19.103
Authors: Susan J Bartlett; Sarah Hewlett; Clifton O Bingham; Thasia G Woodworth; Rieke Alten; Christoph Pohl; Ernest H Choy; Tessa Sanderson; Annelies Boonen; Vivian Bykerk; Amye L Leong; Vibeke Strand; Daniel E Furst; Robin Christensen Journal: Ann Rheum Dis Date: 2012-07-06 Impact factor: 19.103
Authors: Echoe M Bouta; Richard D Bell; Homaira Rahimi; Lianping Xing; Ronald W Wood; Clifton O Bingham; Christopher T Ritchlin; Edward M Schwarz Journal: Nat Rev Rheumatol Date: 2018-01-11 Impact factor: 20.543
Authors: Susan J Bartlett; Skye P Barbic; Vivian P Bykerk; Ernest H Choy; Rieke Alten; Robin Christensen; Alfons den Broeder; Bruno Fautrel; Daniel E Furst; Francis Guillemin; Sarah Hewlett; Amye L Leong; Anne Lyddiatt; Lyn March; Pamela Montie; Christoph Pohl; Marieke Scholte Voshaar; Thasia G Woodworth; Clifton O Bingham Journal: J Rheumatol Date: 2017-08-15 Impact factor: 4.666
Authors: Susan J Bartlett; Vivian P Bykerk; Orit Schieir; Marie-France Valois; Janet E Pope; Gilles Boire; Carol Hitchon; Glen Hazlewood; Louis Bessette; Edward Keystone; Carter Thorne; Diane Tin; Clifton O Bingham Journal: Qual Life Res Date: 2022-09-08 Impact factor: 3.440
Authors: N Barroso; T G Woodworth; D E Furst; F Guillemin; B J Fautrel; N Borazan; S Kafaja; J Brook; D A Elashoff; V K Ranganath Journal: Clin Rheumatol Date: 2019-09-06 Impact factor: 2.980
Authors: D Isenberg; J Sturgess; E Allen; C Aranow; A Askanase; B Sang-Cheol; S Bernatsky; I Bruce; J Buyon; R Cervera; A Clarke; Mary Anne Dooley; P Fortin; E Ginzler; D Gladman; J Hanly; M Inanc; S Jacobsen; D Kamen; M Khamashta; S Lim; S Manzi; O Nived; C Peschken; M Petri; K Kalunian; A Rahman; R Ramsey-Goldman; J Romero-Diaz; G Ruiz-Irastorza; J Sanchez-Guerrero; K Steinsson; G Sturfelt; M Urowitz; R van Vollenhoven; D J Wallace; A Zoma; J Merrill; C Gordon Journal: Arthritis Care Res (Hoboken) Date: 2017-12-08 Impact factor: 4.794
Authors: Lieke Tweehuysen; Cornelia H van den Ende; Fenna M M Beeren; Evelien M J Been; Frank H J van den Hoogen; Alfons A den Broeder Journal: Arthritis Rheumatol Date: 2017-02 Impact factor: 10.995
Authors: Fowzia Ibrahim; Beatriz Lorente-Cánovas; Caroline J Doré; Ailsa Bosworth; Margaret H Ma; James B Galloway; Andrew P Cope; Ira Pande; David Walker; David L Scott Journal: Rheumatology (Oxford) Date: 2017-11-01 Impact factor: 7.580